ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Rosen Law Firm is urging investors in Aardvark Therapeutics (AARD) to join a securities class action lawsuit with an October 13, 2026 deadline for lead plaintiff claims. The lawsuit alleges that defendants made materially false statements about the safety and prospects of their drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.